TVRD · NASDAQ
Tvardi Therapeutics (TVRD) Stock Price & Fundamentals
Tvardi Therapeutics (TVRD) closed at $872.95 on Oct 9, 2026, up 0.21% from the previous close of $871.11.
Share price, past year
1Y +29.73%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $872.95 |
| Sep 30, 2026 | $906.32 |
| Aug 31, 2026 | $916.35 |
| Jul 31, 2026 | $864.06 |
| Jun 30, 2026 | $864.64 |
| May 29, 2026 | $869.13 |
| Apr 30, 2026 | $817.80 |
| Mar 31, 2026 | $768.76 |
| Feb 27, 2026 | $767.98 |
| Jan 30, 2026 | $760.42 |
| Dec 31, 2025 | $710.70 |
| Nov 28, 2025 | $716.46 |
| Oct 31, 2025 | $687.77 |
Key statistics
- Market cap
- $8.19B
- P/E (TTM)
- 21,823.8
- EPS (TTM)
- $0.04
- Revenue (TTM)
- —
- Net income (TTM)
- −$26.06M
- Shares outstanding
- 9.4M
- Dividend yield
- —
- 52-week range
- $657.85 – $952.78
Tvardi Therapeutics's market cap is $8.19B, based on a share price of $872.95 and 9.4M shares outstanding as of Jun 30, 2026.
Financials
Tvardi Therapeutics reported revenue of $7.14M for fiscal 2024, down 65.96% from fiscal 2023.
Tvardi Therapeutics reported a net loss of $18.21M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2024ended Dec 31, 2024 | $7.14M | −66.0% | −$29.40M | −411.9% | −$11.42 | −$19.35M |
| FY2023ended Dec 31, 2023 | $20.97M | −49.9% | −$118.51M | −565.2% | −$26.26 | −$94.45M |
| FY2022ended Dec 31, 2022 | $41.87M | +81.8% | −$85.47M | −204.2% | −$19.12 | −$78.77M |
| FY2021ended Dec 31, 2021 | $23.03M | −83.0% | −$88.44M | −384.1% | −$20.96 | −$60.13M |
| FY2020ended Dec 31, 2020 | $135.08M | +579.3% | $8.41M | 6.2% | $2.17 | −$5.84M |
| FY2019ended Dec 31, 2019 | $19.89M | +47.6% | −$106.37M | −534.9% | −$30.00 | −$109.24M |
| FY2018ended Dec 31, 2018 | $13.47M | +1,378.5% | −$74.01M | −549.5% | −$24.82 | −$22.37M |
| FY2017ended Dec 31, 2017 | $911.00K | +959.3% | −$58.13M | −6,380.4% | −$22.41 | −$54.89M |
| FY2016ended Dec 31, 2016 | $86.00K | −97.7% | −$57.28M | −66,604.7% | −$25.30 | −$48.10M |
| FY2015ended Dec 31, 2015 | $3.80M | — | — | — | — | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q1 FY2025ended Mar 31, 2025 | $2.57M | −$9.58M | −$3.72 |
| Q4 FY2024ended Dec 31, 2024 | $1.46M | −$12.71M | $13.67 |
| Q3 FY2024ended Sep 30, 2024 | $2.56M | −$5.51M | −$2.14 |
| Q2 FY2024ended Jun 30, 2024 | $991.00K | — | — |
| Q1 FY2024ended Mar 31, 2024 | $2.14M | — | — |
| Q4 FY2023ended Dec 31, 2023 | $3.00M | — | — |
| Q3 FY2023ended Sep 30, 2023 | $4.87M | — | — |
| Q2 FY2023ended Jun 30, 2023 | $6.93M | — | — |
Company profile
- Name
- Tvardi Therapeutics, Inc.
- Ticker
- TVRD
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 3 Sugar Creek Ctr. Blvd., Ste 525, Sugar Land, TX 77478
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001346830
Recent SEC filings
- Aug 14, 2026
- Aug 14, 2026
- Jul 30, 2026
- Jul 17, 2026
- Jul 7, 2026
- Jun 11, 2026
- May 8, 2026
- May 8, 2026
Frequently asked questions
What is Tvardi Therapeutics's stock price?
Tvardi Therapeutics (TVRD) closed at $872.95 on Oct 9, 2026, up 0.21% from the previous close of $871.11.
What is Tvardi Therapeutics's market cap?
Tvardi Therapeutics's market cap is $8.19B, based on a share price of $872.95 and 9.4M shares outstanding as of Jun 30, 2026.
How much revenue does Tvardi Therapeutics make?
Tvardi Therapeutics reported revenue of $7.14M for fiscal 2024, down 65.96% from fiscal 2023.
What is TVRD's P/E ratio?
Tvardi Therapeutics's price-to-earnings ratio is 21,823.8, based on trailing twelve-month diluted EPS of $0.04.
Does Tvardi Therapeutics pay a dividend?
Yes. Tvardi Therapeutics declared $0.00 per share in dividends for fiscal 2025.
Sources and methodology
Fundamentals come from Tvardi Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures